Regeneus | Medical company

Regeneus

Phone: +61 2 9499 8010

Add/Update information

Reviews

Tags

• Medical company

25.01.2022 Labor to preserve the R&D Tax Incentive: http://ow.ly/7Pjp30n1zt3

25.01.2022 Dr Charlotte Morgan, RGS Head of R&D presents at ISCT2019 Global Showcase on Regeneus' novel allogeneic stem cell platforms for musculoskeletal and neuropathic pain disorders

25.01.2022 Our new director, Dr Alan Dunton opens up to Stockhead about the global neuropathic pain market

25.01.2022 Regeneus FY18 Results and Business Highlights Presentation: http://ow.ly/BV2r30lC1Gl

25.01.2022 Labor says it will establish a comprehensive 'root and branch' review of research in Australia if it wins the next federal election: http://ow.ly/y0Km30mRMRz

24.01.2022 We are looking forward to this world premier event!!!!

24.01.2022 Regeneus featured in the Australian Financial Review this morning on the positive promise of stem cell therapy, read the article here: http://ow.ly/CUUk50udVUt

23.01.2022 Regeneus are encouraged by the positive data obtained from their first-in-human clinical study for RGSH4K, as it highlights the clinical potential of the autologous tumour vaccine product for the treatment of solid tumours: http://ow.ly/eYkQ30laNbw

22.01.2022 Labor says it will establish a comprehensive root and branch review of research in Australia if it wins the next federal election: http://ow.ly/y0Km30mRMRz

21.01.2022 Alliance for Regenerative Medicine has released their quarterly data report for Q2 2018. This is a great report on the sector. Read it here: http://ow.ly/iv6630lluHY

21.01.2022 Dr Tim Borehams Crucible, featuring Regeneus published in Stockhead this morning: http://ow.ly/jz7B30mF9Gz

20.01.2022 Dr Donald Kuah, the key note speaker, presents the positive trial results for Phase I for Progenza at the Tissue Science and Regenerative Medicine Conference in Singapore #raising global awareness#

20.01.2022 Labor to 'preserve' the R&D Tax Incentive: http://ow.ly/7Pjp30n1zt3

20.01.2022 Leo presented at an investor lunch hosted by Finance News Network, see his presentation here: http://ow.ly/8fNN50udWcL

20.01.2022 AusBiotech has released it's Industry Position Survey....a few key messages - "Australia is preparing for a regenerative medicine revolution" however, "The R&D Tax Incentive remains by far the most critical program in supporting the Government's own stated policy objective - to improve Australia's performance when it comes to the translation of R&D".......https://www.ausbiotech.org/documents/item/562

19.01.2022 Regeneus releases FY18 Results, which includes some very positive highlights from another busy year. Read the report here: http://ow.ly/QUfB30lC1qE

19.01.2022 Dr Duncan Thomson is getting ready to present at the National Federation of Australia-Japan Society's National Conference for 2018, where discussions will be held around gaining a deeper understanding of business relations between the 2 great countries...#newdimensions#

19.01.2022 Alliance for Regenerative Medicine has released its Q3 2018 Sector Data Report, highlighting sector trends and metrics: http://ow.ly/d/8362

19.01.2022 Regeneus appoints new CEO, Leo Lee to accelerate global growth! Leo brings a wealth of skills and experience to the company as it seeks to partner its stem cell technologies in Japan, USA and Europe and emerging markets of China and South Korea http://ow.ly/wZgb30npIW0

19.01.2022 @Regeneus supports @AusBiotech's submission into a Senate Inquiry into the legislative Bill that includes the R&D Tax incentive urging the Inquiry to delay its passage until the impacts are better understood and can be mitigated: http://ow.ly/1Voi30mxwvX

18.01.2022 AusBiotech has released its Industry Position Survey....a few key messages - "Australia is preparing for a regenerative medicine revolution" however, "The R&D Tax Incentive remains by far the most critical program in supporting the Governments own stated policy objective - to improve Australias performance when it comes to the translation of R&D".......https://www.ausbiotech.org/documents/item/562

18.01.2022 Patent to issue provides coverage for the use of Progenza in up to 38 European member states, including the UK, Germany, France and Italy as the European Patent Office issues Notice of Intention to Grant European Patent. Kicking goals and achieving global milestones!!!! http://ow.ly/OSvt30mhfT6

18.01.2022 Regeneus appoints international Directors Dr John Chiplin and Dr Alan Dunton to accelerate global growth strategy for Progenza and Sygenus: http://ow.ly/cvMc50thTX7

17.01.2022 Dr Alan Dunton opens up about the global neuropathic pain market....

16.01.2022 Dr Charlotte Morgan, RGS Head of R&D presents at ISCT2019 Global Showcase on Regeneus novel allogeneic stem cell platforms for musculoskeletal and neuropathic pain disorders

15.01.2022 Regeneus' FY18 Results and Business Highlights Presentation: http://ow.ly/BV2r30lC1Gl

15.01.2022 Leo Lee, the newly-appointed CEO of Regeneus Ltd (ASX:RGS), speaks to Proactive Investors about the companys operations, and the wider scientific field. The company holds a number of patents, and is focusing on global expansion, as it advances treatments in the areas of osteoarthritis, neuropathic pain and dermatology: http://ow.ly/isgL30nvmDJ

14.01.2022 Regeneus revises its strategy to focus on delivering regenerative therapies for the global pain market: http://ow.ly/gRlk50v8GMV

14.01.2022 Stockhead: Regeneus secures valuable US patent as it looks to a licensing deal http://ow.ly/JyWI30kTxe0

12.01.2022 BIO Preview: Some of the highlights of one of the worlds premier life science conventions - Regeneus will be there! http://ow.ly/hu7S50uti1N

12.01.2022 CEO, John Martin's presentation to Shareholders was very well received at our 2018 AGM: http://ow.ly/d/85NL

11.01.2022 Dr Tim Boreham's Crucible, featuring Regeneus published in Stockhead this morning: http://ow.ly/jz7B30mF9Gz

10.01.2022 MTPConnect has released a new report entitled 'Regenerative Medicine: Opportunities for Australia' at the AusBiotech conference today. The report provides a roadmap for elevating the sector so it can successfully compete at a global level: http://ow.ly/le5s30mrd8Y

10.01.2022 Dr Alan Dunton opens up to Stockhead about the global neuropathic pain market http://ow.ly/gJqg50un97T

08.01.2022 Regeneus appoints two new heavyweights onto the Board to help execute its global strategy, targeting the global pain market with Progenza and Sygenus platforms!

07.01.2022 CEO, John Martins presentation to Shareholders was very well received at our 2018 AGM: http://ow.ly/d/85NL

07.01.2022 Regeneus are delighted to be working with Dr Tracy Heng of Monash University on a 3 year collaboration looking at the mechanisms of action of mesenchymal stem cells (MSCs): http://ow.ly/YEoR30mAZsV

06.01.2022 @Regeneus supports @AusBiotechs submission into a Senate Inquiry into the legislative Bill that includes the R&D Tax incentive urging the Inquiry to delay its passage until the impacts are better understood and can be mitigated: http://ow.ly/1Voi30mxwvX

05.01.2022 Another key win for Regeneus http://bit.ly/2EtFa9C RGS.ax

05.01.2022 Regeneus reports positive preclinical trial results for Progenza in treating neuropathic pain: http://ow.ly/fy9d50v8GUc

02.01.2022 Dr Duncan Thomson is getting ready to present at the National Federation of Australia-Japan Societys National Conference for 2018, where discussions will be held around gaining a deeper understanding of business relations between the 2 great countries...#newdimensions#

02.01.2022 BIO Preview: Some of the highlights of one of the world's premier life science conventions - Regeneus will be there! http://ow.ly/hu7S50uti1N

02.01.2022 MTPConnect has released a new report entitled Regenerative Medicine: Opportunities for Australia at the AusBiotech conference today. The report provides a roadmap for elevating the sector so it can successfully compete at a global level: http://ow.ly/le5s30mrd8Y

02.01.2022 Professor Graham Vesey is a very successful biotechnology entrepreneur, technology innovator and scientist, who is highly regarded worldwide for his expertise in developing and securing IP to protect the companys current and future technologies. The allowance by the United States Patent Office to allow a patent for Progenza confirms Grahams strength in this area. The US is one of the hardest markets in the world to get a granted patent and we were absolutely delighted tha...t the breadth of the claims allowed were similar to those granted in Australia and Japan. We know that a granted US patents will open up partnering opportunities for us in the worlds largest regenerative medicine market.. The world is becoming increasingly aware of the importance of exosomes as they become recognised for their benefits as cell-free therapeutics which are included in the secretions - Graham was well ahead of the pack in protecting IP around this area and has set the company in secure territory for the development of the companys cell secretions technology, Sygenus. Graham has been behind the success of over 70 patents or patent applications across multiple patent families for Regeneus, which provides a substantial competitive advantage for the companys product pipeline. http://ow.ly/yABV30kTAe2 See more

02.01.2022 Alliance for Regenerative Medicine presents 2019 Cell & Gene State of the Industry Briefing at the JP Morgan Biotech Showcase, providing an update on clinical progress, the current pipeline, financings and more: http://ow.ly/d/8aYJ

01.01.2022 @Regeneus revises its strategy to focus on delivering regenerative therapies for the global pain market: http://ow.ly/GKnh50v8GPB